Answers are grounded in this paper and cite their sources.
Neurodegenerative disorders such as Alzheimer, Parkinson, Huntington, and amyotrophic lateral sclerosis are an increasing universal health disaster whose disease-modifying treatments are few. The blood-brain barrier limits the penetration of about 98 percent of therapeutic substances, which is the major challenge to an effective delivery of drugs to the central nervous system. Nose-to-brain delivery, which requires the use of the olfactory pathway and trigeminal to deliver the product into the brain bypassing the blood-brain barrier, has become a new form of non-invasive delivery. The use of nanotechnology has facilitated increased drug loading, controlled drug release, increased residence time and targeted drug delivery. This review is a complete study of nanoparticle-based intranasal formulations, which includes the anatomy, nanocarrier systems (polymeric, lipid-based, inorganic, hybrid), therapeutic agents, formulation approaches (mucoadhesive systems, in situ gels), the way of characterization, preclinical evidence, and regulation. In spite of the encouraging preclinical data with excellent brain targeting, clinical translation has obstacles such as inter-individual variability, scale-up in manufacturing and limited brain delivery. The future outlooks are personalized medicine, stimuli-responsive nanocarriers, theranostic platform, and artificial intelligence-driven design, which can lead to effective patient-friendly neurodegenerative disease treatment.
No takes yet. Share an insight, caveat, or question.
Janhvi . (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: